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1. INTRODUCTION {#tbed13604-sec-0001}
===============

Since early December, 2019, China has been experiencing an outbreak of coronavirus disease 2019 (COVID‐19), which is caused by a new coronavirus and first reported in Wuhan, Hubei Province (Zhu et al., [2020](#tbed13604-bib-0036){ref-type="ref"}). This new virus has been proved to be capable of human‐to‐human transmission (Chan et al., [2020a](#tbed13604-bib-0003){ref-type="ref"}; Li et al., [2020](#tbed13604-bib-0016){ref-type="ref"}; Riou & Althaus, [2020](#tbed13604-bib-0022){ref-type="ref"}). Entering January 2020, imported and local infections successively appeared in Shanghai (Cai et al., [2020](#tbed13604-bib-0002){ref-type="ref"}). In order to control the spread of COVID‐19, Shanghai Municipal People\'s Government launched a public health first‐level response on 24 January 2020 (Shanghai Municipal People\'s Government, [2020](#tbed13604-bib-0023){ref-type="ref"}). By 19 February 2020, there had been 333 confirmed cases in Shanghai.

Recent studies have revealed characteristics of early transmission and clinical course of COVID‐19(Chen et al., [2020](#tbed13604-bib-0004){ref-type="ref"}; Huang et al., [2020](#tbed13604-bib-0014){ref-type="ref"}; Li et al., [2020](#tbed13604-bib-0016){ref-type="ref"}; Wang, Yuan, et al., [2020](#tbed13604-bib-0030){ref-type="ref"}; Young et al., [2020](#tbed13604-bib-0033){ref-type="ref"}). Due to the differences in susceptible populations, exposure environments, virus virulence and management mechanisms, characteristics of the disease may vary among different cities, especially in Shanghai, a megacity with a highly mobile population and the highest ageing rate in China (Shanghai Municipal Statistics Bureau, [2018](#tbed13604-bib-0024){ref-type="ref"}). Besides, the results of Shanghai\'s prevention and control work reflected in these data may provide references for other megacities for the prevention and control of COVID‐19. Here, we provide an analysis of the data on 333 confirmed cases to describe the epidemiological and clinical characteristics of COVID‐19 in Shanghai.

2. METHODS {#tbed13604-sec-0002}
==========

2.1. Study design and participants {#tbed13604-sec-0003}
----------------------------------

We conducted a descriptive study of all the 333 confirmed COVID‐19 cases reported in Shanghai in the case reporting system as of February 19th, 2020.

2.2. Case definition {#tbed13604-sec-0004}
--------------------

All the cases were tested positive for COVID‐19 in the laboratory and were diagnosed by clinical experts according to the 5th Diagnosis and Treatment Plan (China Medical Administration, [2020](#tbed13604-bib-0005){ref-type="ref"}). Suspected cases were clinically diagnosed based on symptoms and exposure history, and confirmed cases were those suspected cases with positive results for viral nucleic acid test. The severity of symptoms of COVID‐19 is divided into non‐pneumonia, mild, severe and critical pneumonia. 'Severe' refers to dyspnoea, and respiratory rate ≥ 30/min, blood oxygen saturation ≤ 93%, PaO~2~/ FiO~2~ ratio ≤ 300 mmHg; "critically ill" refers to those cases that present with respiratory failure, or septic shock, or multiple organ dysfunction/ failure (China Medical Administration, [2020](#tbed13604-bib-0005){ref-type="ref"}). We used clinical severity of all patients reported in the case reporting system as of 19 February 2020.

2.3. Data collection {#tbed13604-sec-0005}
--------------------

After cases were reported to Center for Disease Control and Prevention in Shanghai (CDC), field investigation was taken within 24 hr and an epidemiological investigation report was formed. The epidemiological investigation report includes (a) basic demographic information; (b) onset, diagnosis and treatment process; (c) suspicious exposure history within 2 weeks before onset; (d) experts' diagnosis opinions; (e) laboratory results; and (f) prevention and control measures.

Specific information in epidemiological investigation reports was extracted and entered into a database built with Epidata software (Epidata Association). All personally identifiable information was removed during analysis.

2.4. Laboratory test {#tbed13604-sec-0006}
--------------------

Laboratory test was performed according to the *Technical Guidelines for Laboratory Testing of Coronavirus Disease 2019* (Chinese bureau of disease control prevention, [2020](#tbed13604-bib-0006){ref-type="ref"}). Upper and lower respiratory tract specimens were acquired from patients. RNA was extracted and tested by real‐time RT‐PCR. Tests were carried out in biosafety level 2 laboratories. The patient was considered as laboratory tested positive only when two targets, open reading frame 1a or 1b (ORF1ab) and nucleocapsid protein (N), were both positive. Primers and probes are shown in [appendix](#tbed13604-app-0001){ref-type="app"}.

2.5. Statistical analysis {#tbed13604-sec-0007}
-------------------------

Continuous variables were expressed as medians and interquartile ranges (IQR) and compared by using Wilcoxon rank‐sum tests. Categorical variables were summarized as counts and percentages in each category and compared by using chi‐square and Fisher\'s exact tests. All missing data were not imputed or analysed. Multivariate logistic regression analysis was used to analyse the risk factors for severe/critical illness, and variables with *p* \< .2 in univariate analysis were included.

The incubation period was calculated according to three different exposure histories (Backer, Klinkenberg, & Wallinga, [2020](#tbed13604-bib-0001){ref-type="ref"}; Donnelly et al., [2003](#tbed13604-bib-0008){ref-type="ref"}; Goh et al., [2006](#tbed13604-bib-0011){ref-type="ref"}): Cases with a travel history (not living history) in Wuhan.Incubation period of environmental exposure cases (day) = \[(date of onset‐date of arrival in Wuhan) + (date of onset‐date of departure from Wuhan)\]/2.

Cases with multiple exposures to confirmed cases.

Incubation period of cases with multiple exposures to confirmed cases (day) = \[(Date of onset‐date of first contact) + (date of onset‐date of last contact)\]/2.

Cases with single exposure to confirmed cases.

Incubation period of cases with single exposure to confirmed cases (day) = Date of onset‐date of contact.

The incubation period distribution was estimated by fitting a gamma distribution.

Analyses were performed with R software (R Foundation for Statistical Computing). Distribution map was plotted with ArcGis 10.3 (Environmental Systems Research Institute, Inc.).

2.6. Ethics approval {#tbed13604-sec-0008}
--------------------

This study was reviewed and approved by Shanghai Municipal CDC Ethics Review Committee.

3. RESULTS {#tbed13604-sec-0009}
==========

3.1. Demographic characteristics {#tbed13604-sec-0010}
--------------------------------

As shown in Table [1](#tbed13604-tbl-0001){ref-type="table"}, of all the 333 confirmed cases, the ratio between male (172, 51.7%) and female (161, 48.3%) was 1.07:1, the median age was 50 years (IQR, 35 to 63; Range 0 to 88 years). Patients aged 15--45 years (138, 41.4%) and above 60 years (107, 32.1%) accounted for a relatively large amount. As for body mass index (BMI), 19 (5.7%) cases were underweight and 145 (43.5%) cases were overweight. 101(30.3%) cases were retired people, and 4 (1.2%) cases were healthcare workers (Only one of them was infected in medical process). 107 (32.1) cases had anamnesis. 24 (7.4%) cases had a smoking history, and 78 (24.1%) cases had an alcohol history. Most cases (299, 89.8%) had mild pneumonia.

###### 

Demographic characteristics of COVID‐19 cases in Shanghai (*n* = 333)

  Category                                                                         *N* (%)
  -------------------------------------------------------------------------------- -------------------------
  Sex                                                                              
  Female                                                                           161 (48.3)
  Male                                                                             172 (51.7)
  Age, years                                                                       
  Median (\[IQR\], \[range\])                                                      50 \[35, 63\], \[0,88\]
  \<15                                                                             10 (3.0)
  15--44                                                                           138 (41.4)
  45--59                                                                           78 (23.4)
  ≥60                                                                              107 (32.1)
  BMI                                                                              
  \<18.5                                                                           19 (5.7)
  18.5--23.9                                                                       150 (47.6)
  ≥24                                                                              146 (46.3)
  Missing                                                                          18 (5.4)
  Occupation                                                                       
  Staff in service industry                                                        132 (39.6)
  Retiree                                                                          101 (30.3)
  Farmer/worker                                                                    20 (6.0)
  Medical staff                                                                    4 (1.2)
  Other                                                                            61 (18.3)
  Missing                                                                          15 (4.5)
  Anamnesis                                                                        
  Yes                                                                              107 (32.1)
  Diabetes                                                                         28 (8.4)
  High blood pressure                                                              64 (19.2)
  Heart disease                                                                    24 (7.2)
  Respiratory disease                                                              5 (1.5)
  No                                                                               226 (67.9)
  Smoking history                                                                  
  Yes                                                                              26 (7.8)
  No                                                                               265 (79.6)
  Missing                                                                          42 (12.6)
  Alcohol history                                                                  
  Yes                                                                              81 (24.3)
  No                                                                               207 (62.2)
  Missing                                                                          45 (13.5)
  Symptom severity                                                                 
  Non‐pneumonia                                                                    8 (2.4)
  Mild pneumonia                                                                   299 (89.8)
  Severe pneumonia                                                                 10 (3.0)
  Critical pneumonia                                                               16 (4.8)
  Location of the infections                                                       
  Wuhan                                                                            139 (41.7)
  Shanghai                                                                         111 (33.3)
  Other aAreas (three main areas are listed below)                                 83 (24.9)
  Jiang su                                                                         12(3.6)
  An hui                                                                           8(2.4)
  Outside China                                                                    8 (2.4)
  Exposure history                                                                 
  Contact‐confirmed cases                                                          148 (44.4)
  Without clear confirmed case contacts                                            
  With Wuhan sojourn                                                               103 (30.9)
  Contact people with Hubei sojourn                                                21 (6.3)
  Other suspicious sojourn[^a^](#tbed13604-note-0002){ref-type="fn"} or contacts   61 (18.3)

These suspicious places include other places like Ezhou, Huanggang, Huangshi in Hubei and other provinces in China, like Jiangsu, Zhejiang and Anhui.
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As of 19 February 2020, 2 cases died of COVID‐19 and the mortality rate of this disease in Shanghai was 0.06%. One of the dead was an 88‐year‐old man with hypertension, heart disease and chronic obstructive pulmonary disease. The time from onset to death was 5 days. The other deceased was a 79‐year‐old female suffering from hypertension and cerebral infarction. The time from onset to death was 13 days. Both patients underwent active medical treatment, including antiviral, anti‐inflammatory and immune enhancement, but the treatment was not effective.

139 (41.7%) cases were infected in Wuhan and 111 (33.3%) cases in Shanghai. Exploring all the patients' exposure history, we found that 148 (44.4%) cases had clear contacts with confirmed cases. Among those who did not report exposure to confirmed cases, 103 (30.9%) cases had sojourn history in Wuhan, 21 (6.3%) contacted people with sojourn history in Hubei Province, and 61 (18.3%) had been to other suspicious places or had confirmed cases near their residence.

3.2. Spatiotemporal distribution {#tbed13604-sec-0011}
--------------------------------

As shown in Figure [1](#tbed13604-fig-0001){ref-type="fig"}, the onset date of Shanghai\'s first case was 28 December 2019, with the peak was arriving on 27 January 2020. Also, the incidence peak of people infected in Wuhan appeared on 27 January 2020. The number of patients infected in Shanghai gradually increased from 12 January 2020, reaching the peak on 2 February. From 7 February 2020, no cases reported in Shanghai were infected in Wuhan.

![Epidemic curve of 333 confirmed COVID‐19 cases infected in different areas (Wuhan, Shanghai, other areas)](TBED-9999-na-g001){#tbed13604-fig-0001}

Of all the 333 confirmed cases, 242 (72.7%) cases currently live in Shanghai. 3 cases had onset symptoms before 14 January 2020 (stage 1), 74 cases before 24 January 2020 (stage 2), 216 cases before 4 February 2020 (stage 3) and 242 cases before 19 February 2020 (stage 4) (Figure [2](#tbed13604-fig-0002){ref-type="fig"}). In the above stated four stages, the number of streets or towns with confirmed cases was 4, 49, 94 and 101, respectively (Figure [2](#tbed13604-fig-0002){ref-type="fig"}).

![The spatial and temporal distribution of COVID‐19 in Shanghai](TBED-9999-na-g002){#tbed13604-fig-0002}

3.3. Incubation period {#tbed13604-sec-0012}
----------------------

There were 64 cases with a travel history in Wuhan, and the median incubation period was 7.8 days (IQR, 5.0 to 8.2 days; range, 0.5 to 20 days). The gamma distribution fit indicated that the estimated median incubation period was 7.2 days (95% confidence interval \[CI\], 6.1 to 8.4 days) (Figure [3a](#tbed13604-fig-0003){ref-type="fig"}).

![Estimated incubation period distribution (the time from infection to illness onset). (a) Estimated separately according to three types of cases: 64 cases with a travel history in Wuhan area, 57 cases with multiple exposure to confirmed cases and 11 cases with single exposure to confirmed cases. (b) Estimated all the 132 cases with detail contact history information](TBED-9999-na-g003){#tbed13604-fig-0003}

57 cases had multiple exposures to confirmed cases, and the median incubation period was 7.5 days (IQR, 5.0 to 7.9 days; range, 0.5 to 23 days). As shown in the gamma distribution, the estimated median incubation period was 7.0 days (95% CI, 5.9 to 8.1 days) (Figure [3a](#tbed13604-fig-0003){ref-type="fig"}).

11 cases had single exposure to confirmed cases, and the median incubation period was 9.0 days (IQR, 5.0 to 8.0 days; range, 1 to 14 days). As demonstrated in the gamma distribution, the estimated median incubation period was 7.5 days (95% CI, 4.4 to11.8 days) (Figure [3a](#tbed13604-fig-0003){ref-type="fig"}).

We pooled all the 132 cases together to fit the gamma distribution, and the results showed that the estimated median incubation period was 7.2 days (95% CI, 6.4 to 7.9 days), and with the 95th, 99th percentile of the distribution was 16.0 and 20.4 days, respectively (Figure [3b](#tbed13604-fig-0003){ref-type="fig"}).

3.4. Time intervals from onset to visit, hospitalization and diagnosis confirmed {#tbed13604-sec-0013}
--------------------------------------------------------------------------------

As shown in Table [2](#tbed13604-tbl-0002){ref-type="table"}, overall, median onset visit interval of patients was 1.0 days (IQR, 0.0 to 4.0 days) and became shorter after 24 January. Median onset hospitalization interval and onset diagnosis‐confirmed interval was 3.0 (IQR, 1.0 to 6.0) and 5.0 days (IQR, 3.0 to 8.0 days), respectively. Also, onset hospitalization interval and onset diagnosis‐confirmed interval were all shorter after 24 January.

###### 

Time interval distribution before and after 24 January

  Time Interval                               Overall            Before 24 January (include 24 January)   After 24 January   *p*
  ------------------------------------------- ------------------ ---------------------------------------- ------------------ ---------
  Onset visit interval (days)                 1.0 \[0.0, 4.0\]   2.0 \[1.0, 5.0\]                         1.0 \[0.0, 3.0\]   \<0.001
  Onset hospitalization interval (days)       3.0 \[1.0, 6.0\]   5.0 \[2.8, 8.2\]                         2.0 \[0.0, 4.0\]   \<0.001
  Onset diagnosis‐confirmed interval (days)   5.0 \[3.0, 8.0\]   8.0 \[5.0, 10.0\]                        4.0 \[2.0,6.0\]    \<0.001
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3.5. Clinical characteristics {#tbed13604-sec-0014}
-----------------------------

207 (62.2%) cases had fever, 106 (31.8%) had cough, and 40 (12.0%) had fatigue symptoms at the onset (Table [3](#tbed13604-tbl-0003){ref-type="table"}).

###### 

Symptoms of COVID‐19 patients from onset to hospitalization (*n* = 333)

  Symptoms                            Onset                                          Onset to hospitalization
  ----------------------------------- ---------------------------------------------- --------------------------
  Fever                               207 (62.2)                                     273 (82.0)
  Dry cough                           106 (31.8)                                     137 (41.1)
  Fatigue                             40 (12.0)                                      50 (15.0)
  Pharyngalgia                        31 (9.3)                                       39 (11.7)
  Headache                            30 (9.0)                                       36 (10.8)
  Expectoration                       29 (8.7)                                       42 (12.6)
  Myalgia                             25 (7.5)                                       26 (7.8)
  Chill                               20 (6.0)                                       21 (6.3)
  Snivel                              19 (5.7)                                       21 (6.3)
  Nasal congestion                    13 (3.9)                                       13 (3.9)
  Dizziness                           8 (2.4)                                        8 (2.4)
  Chest congestion                    7 (2.1)                                        15 (4.5)
  Diarrhoea                           7 (2.1)                                        11 (3.3)
  Joint sore                          5 (1.5)                                        9 (2.7)
  Polypnoea                           2 (0.6)                                        7 (2.1)
  Dyspnoea                            1 (0.3)                                        4 (1.2)
  Fever + any other symptoms          123 (37.0)                                     199 (59.8)
  Fever + Dry cough                   12 (3.6)                                       28 (8.4)
  Fever + Fatigue                     10 (3.0)                                       10 (3.0)
  Fever + Myalgia                     8 (2.4)                                        8 (2.4)
  Peak temperature (℃, median, IQR)   NA[^a^](#tbed13604-note-0003){ref-type="fn"}   38.0 \[37.7, 38.5\]

NA means data not available.
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From onset to hospitalization, the most common symptom was still fever (82.0%), followed by dry cough (41.1%) and fatigue (15.0%). Respectively, 123 (37.0%) cases experienced fever with other symptoms at the onset, and 199 (59.8%) had fever and other symptoms from onset to hospitalization. The most common combination of symptoms at the onset and from onset to hospitalization was fever with dry cough, fever with fatigue and fever with myalgia. From onset to hospitalization, the median peak temperature in cases with fever symptoms was 38.0°C (IQR, 37.7 to 38.5°C) (Table [3](#tbed13604-tbl-0003){ref-type="table"}).

Of the cases with the first blood routine after the onset, 56 (18.6%) adults showed a decrease in white blood cell count, 1 (0.7%) had an increase in white blood cell count, with statistical difference between female and male. 84 (42.9%) cases had increased C‐reactive protein (Table [4](#tbed13604-tbl-0004){ref-type="table"}). Lots of blood routine data for children were missing. According to the data we have obtained, only 1 (14.3%) of the children\'s white blood cell count decreased.

###### 

First blood routine after onset of Adults (*n* = 323) and Children (*n* = 10)

  Blood routine                                       Adults (*n* = 323)   *p*          Children (*n* = 10)   *p*                                        
  --------------------------------------------------- -------------------- ------------ --------------------- ------- ---------- ----------- ----------- ----------------------------------------------
  White blood cell                                                                                                                                       
  Normal[^b^](#tbed13604-note-0005){ref-type="fn"}    244 (81.1)           108 (73.5)   136 (88.3)            0.002   6 (85.7)   2 (100.0)   4 (80.0)    NA[^a^](#tbed13604-note-0004){ref-type="fn"}
  Decrease                                            56 (18.6)            39 (26.5)    17 (11.0)                     1 (14.3)   0 (0.0)     1 (20.0)     
  Increase                                            1 (0.3)              0 (0.0)      1 (0.6)                       0 (0.0)    0 (0.0)     0 (0.0)      
  Missing[^c^](#tbed13604-note-0006){ref-type="fn"}   22                   10           12                            3          2           1            
  Neutrophil                                                                                                                                             
  Normal[^b^](#tbed13604-note-0005){ref-type="fn"}    229 (97.4)           111 (98.2)   118 (96.7)            0.585   1 (33.3)   1 (100.0)   0 (0.0)     0.223
  Decrease                                            5 (2.1)              2 (1.8)      3 (2.5)                       1 (33.3)   0 (0.0)     1 (50.0)     
  Increase                                            1 (0.4)              0 (0.0)      1 (0.8)                       1 (33.3)   0 (0.0)     1 (50.0)     
  Missing[^c^](#tbed13604-note-0006){ref-type="fn"}   88                   44           44                            7          3           4            
  Lymphocyte                                                                                                                                             
  Normal[^b^](#tbed13604-note-0005){ref-type="fn"}    229 (88.4)           114 (90.5)   115 (86.5)            0.303   4 (66.7)   1 (100.0)   3 (60.0)    0.741
  Decrease                                            28 (10.8)            12 (9.5)     16 (12.0)                     1 (16.7)   0 (0.0)     1 (20.0)     
  Increase                                            2 (0.8)              0 (0.0)      2 (1.5)                       1 (16.7)   0 (0.0)     1 (20.0)     
  Missing[^c^](#tbed13604-note-0006){ref-type="fn"}   64                   31           33                            4          3           1            
  C‐reactive protein                                                                                                                                     
  Normal[^b^](#tbed13604-note-0005){ref-type="fn"}    112 (57.1)           58 (63.7)    54 (51.4)             0.111   4 (80.0)   0 (0.0)     4 (100.0)   0.402
  Increase                                            84 (42.9)            33 (36.3)    51 (48.6)                     1 (20.0)   1 (100.0)   0 (0.0)      
  Missing[^c^](#tbed13604-note-0006){ref-type="fn"}   127                  66           61                            5          3           2            

NA means data not available.

Normal range of white blood cell is 4.0--10.0 × 10^9^/L, except 6.0 \~ 15.0 × \*10^9^/L in child aged 6 month to 6 years; normal range of neutrophil is 1.5 \~ 7.5 × 10^9^/L; normal range of lymphocyte is 0.8 \~ 4.0 × 10^9^/L; normal range of C‐reactive protein is 10 mg/L or less.

All the missing data were not included in the statistical test.
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3.6. Clinical severity analysis {#tbed13604-sec-0015}
-------------------------------

307 cases had non‐ or mild pneumonia, and 26 had severe or critical pneumonia. Univariate analysis showed that older age groups, men and anamnesis especially heart disease were risk factors for severe or critical illness (Table [5](#tbed13604-tbl-0005){ref-type="table"}). In multivariate analysis, for each increase in the age group, the risk of severe/ critical illness increased by 4.33 times; the risk of severe/ critical illness for men was 4.56 times that of women. The risk of severe/ critical illness in people with heart disease was 4.17 times that of people without heart disease (Table [6](#tbed13604-tbl-0006){ref-type="table"}).

###### 

Univariate analysis of clinical severity risk factors

  Category                                            Non‐pneumonia/mild pneumonia(*n* = 307)   Severe/critical pneumonia(*n* = 26)   *p*
  --------------------------------------------------- ----------------------------------------- ------------------------------------- ---------
  Age (median, IQR)                                   47.0 \[34.0, 62.0\]                       65.0 \[63.0, 74.8\]                   \<0.001
  Age group (years)                                                                                                                   
  \<15                                                10 (3.3)                                  0 (0.0)                               \<0.001
  15--44                                              136 (44.3)                                2 (7.7)                                
  45--59                                              75 (24.4)                                 3 (11.5)                               
  ≥60                                                 86 (28.0)                                 21 (80.8)                              
  Sex                                                                                                                                 
  Female                                              155 (50.5)                                6 (23.1)                              0.013
  Male                                                152 (49.5)                                20 (76.9)                              
  BMI                                                                                                                                 
  \<18.5                                              18 (6.2)                                  1 (4.0)                               0.359
  18.5--23.9                                          141 (48.6)                                9 (36.0)                               
  ≥24                                                 131 (45.2)                                15 (60.0)                              
  Missing[^a^](#tbed13604-note-0007){ref-type="fn"}   17                                        1                                      
  Smoking history                                                                                                                     
  Yes                                                 24 (8.9)                                  2 (8.0)                               1
  No                                                  246 (91.1)                                23 (92.0)                              
  Missing[^a^](#tbed13604-note-0007){ref-type="fn"}   37                                        1                                      
  Alcohol history                                                                                                                     
  Yes                                                 76 (28.9)                                 5 (20.0)                              0.546
  No                                                  187 (71.1)                                20 (80.0)                              
  Missing[^a^](#tbed13604-note-0007){ref-type="fn"}   44                                        1                                      
  Anamnesis                                                                                                                           
  Yes                                                 91 (29.6)                                 16 (61.5)                             0.002
  No                                                  216 (70.4)                                10 (38.5)                              
  Diabetes                                                                                                                            
  Yes                                                 23 (7.01835)                              5 (19.2)                              0.089
  No                                                  284 (92.5)                                21 (80.8)                              
  High blood pressure                                                                                                                 
  Yes                                                 55 (17.9)                                 9 (34.6)                              0.069
  No                                                  252 (82.1)                                17 (65.4)                              
  Heart disease                                                                                                                       
  Yes                                                 16 (5.2)                                  8 (30.8)                              \<0.001
  No                                                  291 (94.8)                                18 (69.2)                              
  Respiratory disease                                                                                                                 
  Yes                                                 3 (1.0)                                   2 (7.7)                               0.062
  No                                                  304 (99.0)                                24 (92.3)                              
  Onset visit interval                                1.0 \[0.0, 4.0\]                          1.0 \[0.0, 4.0\]                      0.386
  Onset hospitalization interval                      3.0 \[1.0, 6.0\]                          3.0 \[2.0, 6.0\]                      0.291
  Onset diagnosis‐confirmed interval                  5.0 \[3.0, 8.0\]                          5.0 \[3.0, 8.5\]                      0.602

All the missing data were not included in the statistical test.
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###### 

Multivariate analysis of clinical severity risk factors

  Factor                *β*    Standard Error   OR    OR 95% CI   *p*P
  --------------------- ------ ---------------- ----- ----------- ---------
  Intercept             −7     1.1                                \<0.001
  Age group             1.5    0.4              4.3   2.1--9.1    \<0.001
  Sex                   1.5    0.5              4.6   1.7--12.6   0.003
  Heart disease         1.4    0.6              4.2   1.2--14.2   0.024
  Diabetes              0.1    0.6              1.1   0.3--3.6    0.884
  High blood pressure   −0.4   0.6              0.7   0.2--2.0    0.495
  Respiratory disease   0.7    1.1              2.0   0.2--18.3   0.538

Age group ( \<15 = 1, 15--44 = 2, 45--59 = 3, ≥60 = 4),age group \< 15 was used as the reference; sex(female = 1, male = 2),female was used as the reference; heart disease, diabetes, high blood pressure, respiratory disease(no = 1, yes = 2), the status no was used as the reference.
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4. DISCUSSION {#tbed13604-sec-0016}
=============

Seen from the perspective of the infected areas, the cases in Shanghai were mainly imported. However, due to the nature of human‐to‐human transmission, the number of patients infected in Shanghai had gradually increased, which indicates that the COVID‐19 has a strong ability to transmit between humans. In order to control the disease, Shanghai launched first‐level public health response on 24 January 2020 (Shanghai Municipal People\'s Government, [2020](#tbed13604-bib-0023){ref-type="ref"}). After the response was launched, Shanghai Municipal People\'s Government integrated resources to deal with the epidemic. All group activities were cancelled; masks were recommended to be worn in public places, and fever monitoring was conducted at the exit and entry points. Shanghai residents cooperated with the government by staying indoors. After 24 January 2020, although the number of cases peaked on 27 January, the number of new cases decreased significantly within two weeks, and kept at a low level after 8 February 2020 (Figure [1](#tbed13604-fig-0001){ref-type="fig"}). The time intervals from onset to visit, hospitalization and diagnosis confirmed were all shortened. The mortality rate of COVID‐19 in Shanghai was only 0.06%, much lower than that of mainland China (2.3%) (Novel Coronavirus Pneumonia Emergency Response Epidemiology Team, [2020](#tbed13604-bib-0021){ref-type="ref"}). Another international metropolis, New York, reported a cumulative 26,697 cases from 1 March 2020 to 27 March 2020, with no downward trend (NYC Health, [2020](#tbed13604-bib-0013){ref-type="ref"}). But Shanghai has had only 333 cases in over 1.5 months and has brought the local outbreak under control. These data manifested the effectiveness of the powerful prevention and control measures in Shanghai.

The median age of Shanghai\'s cases was 50 years old, which was older than those in Beijing (47.5 years old) (Tian et al., [2020](#tbed13604-bib-0027){ref-type="ref"}) and New York (47 years old) (NYC Health, [2020](#tbed13604-bib-0013){ref-type="ref"}), possibly for the reason of the city\'s ageing population(Shanghai Municipal Statistics Bureau, [2018](#tbed13604-bib-0024){ref-type="ref"}). Of the 10 children cases in Shanghai, 7 were infected by their family members and all children cases had mild symptoms (7 non‐pneumonia, 3 mild pneumonia). In concert with other research (Wang, Yuan, et al., [2020](#tbed13604-bib-0030){ref-type="ref"}), children cases account for only a small ratio of all age groups in Shanghai and had milder symptoms, but the reasons remain unclear. Considering that some studies suggest that the expression of the receptor for COVID‐19, which was currently regarded as angiotensin‐converting enzyme 2 (ACE2) (Zhou et al., [2020](#tbed13604-bib-0035){ref-type="ref"}), is not lower in children compared to that in adults (Xie, Chen, Wang, Zhang, & Liu, [2006](#tbed13604-bib-0032){ref-type="ref"}), we suspect that fewer trips and less socializing in children lead to the lower morbidity, or simply because symptoms in children are milder and harder to detect. The less severe symptoms in children may be due to their different immune mechanisms from those of adults.

There are two facts worth discussing about the exposure history. One was that 103 cases had sojourned Wuhan without contacting confirmed cases and the other one was that 21 cases contacted people sojourning in Hubei but not confirmed cases. In our investigation, most of these patients did not even notice that people they contacted had symptoms like fever or cough. Mahase E pointed out that many asymptomatic or mildly infected people may scatter in the community as sources of infection (Mahase, [2020](#tbed13604-bib-0019){ref-type="ref"}). And a familial cluster analysis indicated that patients in the incubation period may also be contagious (Chan et al., [2020b](#tbed13604-bib-0003){ref-type="ref"}). Our investigation supported their opinions that asymptomatic and latent infections may become the focus of further prevention and control.

In our calculation, cases with single exposure to confirmed cases had a longer median incubation period (9.0 days) than those with a travel history in Wuhan (7.8 days) and multiple exposures to confirmed cases (7.5 days). This may be attributed to the greater amounts of pathogens that the patients were exposed to on account of the prolonged or multiple exposures. After pooling data and fitting gamma distribution, we estimated that the median incubation period was 7.2 days. However, our results showed a difference from other researches (Backer et al., [2020](#tbed13604-bib-0001){ref-type="ref"}; Guan et al., [2020](#tbed13604-bib-0012){ref-type="ref"}; Ki & nCo, [2020](#tbed13604-bib-0015){ref-type="ref"}; Li et al., [2020](#tbed13604-bib-0016){ref-type="ref"}), of which the median incubation period ranged from 3.0 to 6.4 days. Most articles did not announce their calculation methods, and the cases used to calculate in these articles were mainly travellers (Backer et al., [2020](#tbed13604-bib-0001){ref-type="ref"}; Ki & nCo, [2020](#tbed13604-bib-0015){ref-type="ref"}; Li et al., [2020](#tbed13604-bib-0016){ref-type="ref"}). It is possible that the authors of these articles directly subtracted the date of travellers' departure from the date of onset when calculating incubation period, but the date of leaving infected areas is not necessarily the date of exposure. This algorithm underestimates the incubation period. Our method of choosing patients with clear earliest and last exposure time or single exposure time to estimate incubation period was more reasonable.

The clinical symptoms of COVID‐19 include fever and cough, which are not specific compared with influenza or other respiratory diseases (Fajardo‐Dolci et al., [2010](#tbed13604-bib-0009){ref-type="ref"}; Mohammad, Korn, Schellhaas, Neurath, & Goertz, [2019](#tbed13604-bib-0020){ref-type="ref"}; Shiley, Nadolski, Mickus, Fishman, & Lautenbach, [2010](#tbed13604-bib-0025){ref-type="ref"}). However, though some of the patients (37.8%) did not have fever at onset, most patients (82.0%) indeed experienced fever from onset to hospitalization. This suggests that screening patients for fever symptoms is relatively effective. In our study, we found that most patients had normal white blood cell count, neutrophil and lymphocyte level, but 42.9% of the adults' cases experienced an increasing C‐reactive protein in their first blood routine after onset (Table [4](#tbed13604-tbl-0004){ref-type="table"}), which was consistent with other researches (Singhal, [2020](#tbed13604-bib-0026){ref-type="ref"}). Though elevated C‐reactive protein is not expected with viral infections, Hakan Cinemre et.al found that C‐reactive protein levels can increase in influenza‐like illness and acute respiratory infection when the aetiology is influenza. They also suspected that this might be explained by tissue destruction (Cinemre et al., [2016](#tbed13604-bib-0007){ref-type="ref"}). Since most patients with COVID‐19 have systemic symptoms similar to influenza, the two kinds of infection may share the same mechanism of elevated C‐reactive protein. It is possible to combine changes in C‐reactive proteins with other tests, such as CT imaging to discriminate the infection of COVID‐19, and further studies are needed.

Consistent with other researches (Novel Coronavirus Pneumonia Emergency Response Epidemiology, [2020](#tbed13604-bib-0021){ref-type="ref"}; Wang, Chen, Lu, Chen, & Zhang, [2020](#tbed13604-bib-0031){ref-type="ref"}), the number of male patients (51.7%) was slightly higher than that of female patients (48.3%) in Shanghai. The proportion of men (76.0%) in our severely or critically ill patients, however, was much higher than that of women (24.0%). Current research suggests that ACE2 is the receptor for COVID‐19 (Zhou et al., [2020](#tbed13604-bib-0035){ref-type="ref"}), and its expression in men is higher than that in women (Zhao et al., [2020](#tbed13604-bib-0034){ref-type="ref"}), which may be the reason for the higher proportion of men with severe illness. People with heart disease or in older age groups tend to be more severely ill, perhaps because their immune systems are weak. Considering these risk factors for severe/critical illness, it is understandable that two fatal cases in Shanghai both had an old age and suffered from underlying diseases (one patient had heart disease). Interestingly, smoking is not associated with the severity of the disease, and that may be due to the levels of ACE2 are lower in smokers (Wan, Shang, Graham, Baric, & Li, [2020](#tbed13604-bib-0028){ref-type="ref"}). This discovery was not consistent with the study of Liu W et.al (Liu et al., [2020](#tbed13604-bib-0018){ref-type="ref"}), but in concert with a meta‐analysis (Lippi & Henry, [2020](#tbed13604-bib-0017){ref-type="ref"}). However, diabetes and hypertension are to a certain extent associated with diseases severity, but there is no statistical significance. However, they are risk factors for severe symptoms in other studies (Fang, Karakiulakis, & Roth, [2020](#tbed13604-bib-0010){ref-type="ref"}), and our sample size may be limited to finding a statistical significance.

This study has several limitations. First, some cases have incomplete documentation of smoking history, alcohol history and clinical features. Second, our sample size is limited, especially for sever or critical patients, which may lead to some meaningful results being ignored.

5. CONCLUSIONS {#tbed13604-sec-0017}
==============

In summary, the prevention and control measures in Shanghai are effective. Most patients have mild symptoms and experience fever. Elderly, male and heart disease history is the risk factors for severe or critical pneumonia. It is necessary to strengthen the health management of these groups.
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1.1. Primers and probes of ORF1ab and N gene {#tbed13604-sec-1001}
============================================

ORF1ab: forward primer CCCTGTGGGTTTTACACTTAA; reverse primer ACGATTGTGCATCAGCTGA; probe 5′‐FAM‐CCGTCTGCGGTATGTGGAAAGGTTATGG‐BHQ1‐3′.

N: forward primer GGGGAACTTCTCCTGCTAGAAT; reverse primer CAGACATTTTGCTCTCAAGCTG; probe 5′‐FAM‐ TTGCTGCTGCTTGACAGATT‐TAMRA‐3′.
